.12
  Price6.19%   -0.0076
(Pre-market: .12 +0 +0.00%)
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for immuno-oncology, genetic disorders, and other indications. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis. Exicure, Inc. has collaboration agreements with Allergan plc; DERMELIX, LLC; and Purdue Pharma L.P. The company was founded in 2011 and is headquartered in Skokie, Illinois.
Cap:    |  Volume (24h):